Zai Lab Limited
NASDAQ:ZLABBiotechnology
+$0.61 today
- Market cap
- $2.49B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
Volume 1.04M
Average 0.87M
ZLAB Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Zai Lab LimitedNASDAQ: ZLAB
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity falls 23.3% from a year ago
Total equity stood at $607.04M at the end of Q2 FY2026, down 23.3% from a year earlier and down 8.3% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.
Context
- Total equity amounted to 56.5% of total assets at the end of Q2 FY2026, down 11.5 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -23.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 715.5M USD
- Year-over-year change
- -14.9%
- 4-year CAGR
- -15.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 715.5M | -14.9% |
| FY2024 | 2024-12-31 | 840.9M | +5.6% |
| FY2023 | 2023-12-31 | 796.12M | -23.9% |
| FY2022 | 2022-12-31 | 1.05B | -24.2% |
| FY2021 | 2021-12-31 | 1.38B | — |
Total Equity vs competitors
How ZLAB compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -23.3% is the 3rd highest of 4, against a peer median of +62.1%.
- Total equity amounts to 56.5% of total assets for ZLAB, versus a peer median of 33.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.34B CNY | +387.0% | +48.4% | 33.7% |
| Dec 2025 | $1.25B USD | +62.1% | +25.2% | 71.4% | |
| Jun 2026 | $607.04M USD | -23.3% | -11.9% | 56.5% | |
| Dec 2025 | -$8.32M USD | -132.7% | — | 24.2% | |
| Peer median (excluding ZLAB) | — | +62.1% | +36.8% | 33.7% | |
Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 964.1M | 1.01B | 790.15M | 449.67M | 679.57M |
| Short-term Investments | 445M | 0 | 16.3M | 330M | 10M |
| Net Receivables | 54.81M | 48.57M | 65.33M | 89.41M | 106.12M |
| Inventory | 18.95M | 31.62M | 44.83M | 39.88M | 74.75M |
| Other Current Assets | 0 | 35.67M | 23M | 141.53M | 148.85M |
| Total Current Assets | 1.5B | 1.12B | 939.61M | 1.05B | 1.02B |
| Property, Plant & Equipment (Net) | 58.28M | 78.77M | 68.69M | 69.48M | 66.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.66M | 8.4M | 16.46M | 58.93M | 76.14M |
| Long-term Investments | 15.61M | 6.43M | 9.22M | 3.12M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 3.39M |
| Other Non-current Assets | 25.53M | 2.2M | 2.32M | 3.75M | 7.02M |
| Total Non-current Assets | 109.08M | 95.8M | 96.69M | 135.27M | 153.1M |
| Total Assets | 1.61B | 1.22B | 1.04B | 1.19B | 1.17B |
| Account Payables | 126.16M | 65.97M | 112.99M | 100.91M | 141.61M |
| Short-term Debt | 0 | 0 | 0 | 131.71M | 204.53M |
| Tax Payables | 8.82M | 13.28M | 16.99M | 5.15M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.42M | 4.05M | 5.35M | 6.35M | 7.07M |
| Total Current Liabilities | 192.9M | 139.84M | 203.07M | 299.39M | 416.17M |
| Long-term Debt | 0 | 0 | 0 | 0 | 13.39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 27.49M | 21.36M | 28.74M | 31.43M | 0 |
| Other Non-current Liabilities | 0 | 0 | 325K | 325K | 27.33M |
| Total Non-current Liabilities | 37.1M | 34.7M | 37.11M | 45.47M | 40.72M |
| Total Liabilities | 230M | 174.55M | 240.18M | 344.86M | 456.88M |
| Common Stock | 6K | 6K | 6K | 7K | 7K |
| Retained Earnings | (1.42B) | (1.86B) | (2.2B) | (2.45B) | (2.63B) |
| Accumulated OCI | (23.65M) | 25.69M | 37.63M | 50.52M | 29.7M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.38B | 1.05B | 796.12M | 840.9M | 715.5M |
| Total Debt | 15.54M | 20.39M | 15.15M | 153.47M | 224.26M |
| Net Debt | (948.56M) | (988.08M) | (775M) | (296.2M) | (455.31M) |
Zai Lab Limited
NASDAQ:ZLAB
Intrinsic Alpha fair value
Locked
Current Price
$22.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.